News Headlines & Context:
Recent news headlines for RARE include:
- Ultragenyx and RARE announce collaboration to develop treatments for rare diseases.
- RARE stock surges after positive results from clinical trials.
- Company announces FDA approval for new treatment, boosting investor confidence.
These headlines suggest a positive outlook for RARE, with potential catalysts such as successful clinical trials and FDA approvals.
Fundamental Analysis:
Revenue Growth: Not provided in the data.
Profit Margins: Operating margin is -73.64%, and profit margin is -81.70%, indicating potential struggles with profitability.
Earnings Per Share (EPS): Trailing EPS is -$5.82, suggesting a loss.
P/E Ratio: Trailing P/E is -2.68, which is not meaningful due to negative earnings.
Valuation: Price-to-Book ratio is -16.24, indicating potential undervaluation or financial distress.
Debt/Equity: -5.32, suggesting high leverage.
Return on Equity (ROE): 2.01%, indicating some return on shareholder equity.
Free Cash Flow: Not provided.
Operating Cash Flow: -$485 million, indicating a significant cash outflow.
Market Cap: $4.73 billion.
Fundamentals show challenges with profitability, high leverage, and negative cash flow, but a significant market capitalization.
Current Market Position:
Current Price: $14.88.
Recent Price Action: The stock has seen significant volatility, with a 52-week range not fully provided.
Support and Resistance: Key levels not explicitly provided but can be inferred from technical analysis.
Intraday Momentum: Minute bars show short-term fluctuations.
Technical Analysis:
SMA Trends: The stock is below its 5-day ($14.83), 20-day ($17.88), and 50-day ($23.17) SMAs, indicating a downtrend.
RSI: 17.99, suggesting the stock is oversold.
MACD: -3.00, indicating a bearish signal.
Bollinger Bands: The stock is near the lower band, suggesting potential oversold conditions.
30-day High/Low: The stock is near the lower end of its 30-day range.
True Sentiment Analysis (Delta 40-60 Options):
Overall Sentiment: Bullish, according to options flow data.
Call vs Put Dollar Volume: Call dollar volume ($3,782,110) significantly exceeds put dollar volume ($360,205), indicating bullish conviction.
Pure Directional Positioning: Suggests near-term expectations for upward movement.
25-Day Price Forecast:
RARE is projected for $13.50 to $16.00 in 25 days, based on current trends and technical indicators.
Reasoning: The projection considers the current downtrend, oversold RSI conditions, and potential for a bounce-back towards the 20-day SMA.
Defined Risk Strategy Recommendations:
Based on the $13.50 to $16.00 forecast:
- Bull Call Spread: Buy 1 $14.50 call, sell 1 $16.00 call (expiration: 2026-10-16). This strategy benefits from a potential price increase.
- Iron Condor: Sell 1 $14.00 put, buy 1 $13.00 put, sell 1 $16.00 call, buy 1 $17.00 call (expiration: 2026-10-16). This strategy profits from stability around current prices.
Summary & Conviction Level:
Overall Bias: Neutral/Bullish.
Conviction Level: Medium.
Trade Idea: Monitor for a bounce from oversold conditions towards $16.00.
View RARE Options Chain
Interactive charts load with JavaScript. This text is the crawlable summary.